Bio-Rad Laboratories, Inc. (BIO)
NYSE: BIO · Real-Time Price · USD
280.08
-5.55 (-1.94%)
Feb 21, 2025, 4:00 PM EST - Market closed
Bio-Rad Laboratories Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for Bio-Rad Laboratories stock have an average target of 414, with a low estimate of 340 and a high estimate of 481. The average target predicts an increase of 47.81% from the current stock price of 280.08.
Analyst Consensus: Strong Buy
* Price targets were last updated on Jan 14, 2025.
Analyst Ratings
The average analyst rating for Bio-Rad Laboratories stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 2 | 2 | 2 | 2 | 2 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 2 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| RBC Capital | RBC Capital | Buy Reiterates $481 | Buy | Reiterates | $481 | +71.74% | Jan 14, 2025 |
| RBC Capital | RBC Capital | Buy Maintains $369 → $481 | Buy | Maintains | $369 → $481 | +71.74% | Dec 9, 2024 |
| Citigroup | Citigroup | Strong Buy Maintains $400 → $450 | Strong Buy | Maintains | $400 → $450 | +60.67% | Oct 31, 2024 |
| RBC Capital | RBC Capital | Buy Maintains $446 → $469 | Buy | Maintains | $446 → $469 | +67.45% | Oct 31, 2024 |
| Citigroup | Citigroup | Hold → Strong Buy Upgrades $350 → $400 | Hold → Strong Buy | Upgrades | $350 → $400 | +42.82% | Oct 1, 2024 |
Financial Forecast
Revenue This Year
2.67B
from 2.57B
Increased by 4.19%
Revenue Next Year
2.80B
from 2.67B
Increased by 4.75%
EPS This Year
11.55
from -65.36
EPS Next Year
13.06
from 11.55
Increased by 13.10%
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| High | 2.8B | 2.9B | 3.0B | |
| Avg | 2.7B | 2.8B | 2.9B | |
| Low | 2.6B | 2.7B | 2.8B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| High | 9.1% | 10.3% | 8.5% | |
| Avg | 4.2% | 4.7% | 4.3% | |
| Low | -0.1% | 0.3% | 1.2% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| High | 12.18 | 13.78 | 13.03 | |
| Avg | 11.55 | 13.06 | 12.53 | |
| Low | 10.98 | 12.49 | 12.16 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| High | - | 19.3% | -0.2% | |
| Avg | - | 13.1% | -4.0% | |
| Low | - | 8.1% | -6.9% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.